BiotechTube
MExbrain

MExbrain

Paris, France· Est.
mexbrain.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MexBrain is a 2021 spin-off from the University of Lyon, pioneering a medical device approach to treating metal toxicity. Its core technology is MEX-CD1, a patented, non-absorbable polymer that chelates free metals during dialysis. The company is currently conducting two pilot clinical trials in Europe (MEXWILS and MEXACLF) and holds ISO 13485 certification for its device design and manufacturing. As a private, pre-revenue entity, it is positioned to address significant unmet needs in rare and acute diseases.

Wilson's DiseaseAcute Kidney InjuryMetal Toxicity

Technology Platform

Patented superchelating polymer (MEX-CD1) used in dialysis dialysate to extracorporeally and selectively bind free metal ions without crossing into the bloodstream.

Opportunities

The platform addresses acute, high-need conditions with limited treatment options, allowing for potential premium pricing.
The technology's applicability to a wide range of metal toxicity disorders, from rare diseases to broader conditions like drug intoxication, provides significant pipeline expansion potential.

Risk Factors

Clinical failure in ongoing pilot trials is the primary risk.
Future regulatory hurdles for a novel device-biologic combination product and challenges in achieving market adoption against established standards of care pose significant commercial risks.

Competitive Landscape

Competition includes traditional systemic chelators (e.g., D-penicillamine, deferoxamine) and other liver support/detoxification devices. MexBrain's key differentiator is the localized, non-absorbed action of its polymer, aiming for a superior safety profile compared to systemic therapies.

More companies in Biologics / Biosimilars →More companies in France →